{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00031",
  "@type" : "Drug",
  "administrationRoute" : "intravenous",
  "availableStrength" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:22c29e17b554c3579f072e57155dd8fd",
    "@type" : "DrugStrength",
    "description" : "50 mg Powder for solution form with intravenous route"
  },
  "clinicalPharmacology" : "Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.",
  "cost" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:d1e21d28536ec281a21433a01a301ae5",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "3238.760009765625",
    "drugUnit" : "Tnkase 50 mg kit"
  },
  "description" : "Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.",
  "dosageForm" : "Powder for solution",
  "drugClass" : [ "Thrombolytic Agents", "Fibrinolytic Agents" ],
  "identifier" : "drugbank:DB00031",
  "interactingDrug" : [ "DDI between Tenecteplase and Levomilnacipran - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Citric Acid - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Treprostinil - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Ticagrelor - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Naproxen - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Heparin - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Bivalirudin and Tenecteplase - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Aprotinin - May diminish the therapeutic effect of Thrombolytic Agents.", "DDI between Tenecteplase and Citalopram - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Iloprost - May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.", "DDI between Tenecteplase and Acetylsalicylic acid - May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Phenindione - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Fenoprofen - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Duloxetine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Venlafaxine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Sulodexide - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Rivaroxaban - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Dipyridamole - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Nabumetone - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Floctafenine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Aminosalicylic Acid - Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Abciximab - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Magnesium salicylate - Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Vilazodone - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Dalteparin - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Escitalopram - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Sertraline - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Paroxetine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Clopidogrel - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Prasugrel - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Oxaprozin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Piroxicam - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Salicylate-sodium - May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Indomethacin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Enoxaparin - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Diflunisal - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Desvenlafaxine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Etodolac - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Sulindac - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Milnacipran - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Bismuth Subsalicylate - Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Ticlopidine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Meloxicam - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Phenprocoumon - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Danaparoid - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Tirofiban - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Ketorolac - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Tolmetin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Edetic Acid - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Argatroban - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Ketoprofen - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Vorapaxar - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Dicoumarol - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Epoprostenol - May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.", "DDI between Tenecteplase and Tinzaparin - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Anagrelide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Tiaprofenic acid - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Acenocoumarol - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Apixaban - May enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Salsalate - Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.", "DDI between Tenecteplase and Fluoxetine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Fondaparinux sodium - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Warfarin - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Ibuprofen - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Dabigatran etexilate - Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.", "DDI between Tenecteplase and Mefenamic acid - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Cilostazol - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Ethyl biscoumacetate - Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.", "DDI between Tenecteplase and Fluvoxamine - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Tenecteplase and Nadroparin - May enhance the anticoagulant effect of Anticoagulants." ],
  "legalStatus" : "Approved",
  "mechanismOfAction" : "Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.",
  "name" : "Tenecteplase",
  "nonProprietaryName" : [ "tPA", "t-plasminogen activator", "Tissue-type plasminogen activator precursor", "t- PA" ],
  "sameAs" : [ "http://www.rxlist.com/cgi/generic2/tenecteplase.htm", "http://www.drugs.com/mtm/tenecteplase.html", "http://www.drugbank.ca/drugs/DB00031" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00031.html"
}